| Help us to promote this site! Link to us |
|
|
|
||||
| Email This Page to Friend | |||||
|
Breast Cancer News
|
||||
|
5 Oct 2008 at 7:00pm American Cancer Society - For women facing radiation therapy after surgery for breast cancer, the standard course of treatment typically involves daily radiation sessions over a period of 6 to 7 weeks. That regimen can be hard to manage, especially for women already juggling work and child care schedules or for those living far from treatment centers. 4 Oct 2008 at 12:47am HealthDay - FRIDAY, Oct. 3 (HealthDay News) -- A simple urine test could one day be an effective way to screen for breast cancer, a new study suggests. 2 Oct 2008 at 9:41am Reuters - Hypnosis can help reduce hot flashes among breast cancer survivors, new research published in the Journal of Clinical Oncology shows. 1 Oct 2008 at 8:02pm AP - A computer is as good as a second pair of eyes for helping a radiologist spot breast cancer on a mammogram, one of the largest and most rigorous tests of computer-aided detection found. 1 Oct 2008 at 4:02pm Reuters - Computer software designed to look for breast tumors can read mammograms nearly as well as an extra pair of human eyes, according to a study published on Wednesday that could change the way the X-rays are read. 30 Sep 2008 at 11:18pm Reuters - Vitamin C supplements may undercut the effectiveness of cancer drugs including Novartis' Gleevec, a U.S. study published on Wednesday showed. 30 Sep 2008 at 10:46pm HealthDay - TUESDAY, Sept. 30 (HealthDay News) -- Women who are heavier and longer at birth are at increased risk of developing breast cancer later in life, British researchers report. 30 Sep 2008 at 1:38pm Reuters - Women who were bigger and longer babies may be more likely to develop breast cancer, researchers reported on Tuesday. 29 Sep 2008 at 11:54am Reuters - Breast cancer survivors report feeling more fatigue and negative emotions in a typical day than their cancer-free peers, but round-the-clock monitoring demonstrates that their vital signs and level activity are no different, according to an international study. |
3 Oct 2008 at 6:18am A number of breast cancer cells facing potentially lethal antiestrogen treatment recycle to survive, scientists say. About 70 percent of breast cancer cells have receptors for the hormone estrogen, which acts as a nutrient and stimulates their growth. Patients typically get an antiestrogen such as tamoxifen for five years to try to starve them to death, says Dr. Patricia V. Schoenlein, cancer researcher in the Medical College of Georgia Schools of Medicine and Graduate Studies........3 Oct 2008 at 6:18am  Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, as per a new study published in PLoS Medicine by scientists at the London School of Hygiene and Tropical Medicine. Associations between birth size, perhaps as a marker of the pre-natal environment, and subsequent breast cancer risk have been identified before, but the findings from epidemiological studies have been inconsistent........3 Oct 2008 at 6:18am  Young women with DCIS, a common form of early breast cancer that arises in and is confined to the mammary ducts, are presumed more likely to have recurrences than older women with the same diagnosis. But a new study from Fox Chase Cancer Center rebuffs this conventional thinking. "There are discrepancies among past studies that looked at the outcomes of very young women with DCIS treated with radiation, but a number of suggested a less favorable outcome than for older women," explains Aruna Turaka, MD, a fellow in the Department of Radiation Oncology at Fox Chase. "Because each of these studies reflects diverse factors, including how the cancer was managed by the surgeons and radiation oncologists, we wanted to look at our institution's experience in treating DCIS in this population"........3 Oct 2008 at 6:18am  Boston Accelerated partial breast irradiation (APBI) using a type of radiation seed implants called balloon brachytherapy, a newer type of radiation therapy that offers more convenience to early-stage patients with breast cancer by shortening radiation treatment from the standard six to seven weeks of therapy to only one week, is as effective in keeping breast cancer from coming back as the standard external beam radiation therapy, as per a research studypresented September 22, 2008, at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting in Boston........3 Oct 2008 at 6:18am  Boston Acupuncture is as effective and longer-lasting in managing the common debilitating side effects of hot flashes, night sweats, and excessive sweating (vasomotor symptoms) linked to breast cancer therapy and has no therapy side effects in comparison to conventional drug treatment, as per a first-of-its-kind study presented September 24, 2008, at the American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting in Boston........3 Oct 2008 at 6:18am  The simple application of a pain-relieving gel may reduce the breast discomfort some women experience during mammography exams, as per the results of a clinical trial reported in the online edition of Radiology "We now have something that we know reduces discomfort with screening mammography in women who expect higher discomfortlidocaine gel," said the trial's principal investigator, Colleen Lambertz, F.N.P., a nurse practitioner at St. Luke's Mountain States Tumor Institute in Boise, Idaho. "With a more positive experience, we hope women will undergo more regular mammography screening"........3 Oct 2008 at 6:18am  Research reported today should provide relief to women who are worried after a relative's breast cancer diagnosis. The study in the open access journal BMC Cancer shows that a family history of breast cancer does not give a useful indication of the likelihood that a woman will develop it herself at an early age........3 Oct 2008 at 6:18am  Whether a painless, portable device that uses electrical current rather than X-ray to look for breast cancer could be an alternative to traditional mammograms is under study at the Medical College of Georgia. MCG is one of 20 centers internationally and the only place in Georgia studying new technology developed by Z-Tech Inc., to compare traditional mammograms with impedence scanning, a technique based on evidence that electrical current passes through malignant tissue differently than through normal tissue........3 Oct 2008 at 6:18am  Scientists at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth........3 Oct 2008 at 6:18am  A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, as per a new study from the University of Michigan Comprehensive Cancer Center. The gene, HER2, causes cancer stem cells to multiply and spread, explaining why HER2 has been associated with a more aggressive type of breast cancer and to metastatic disease, in which the cancer has spread beyond the breast, the scientists say........3 Oct 2008 at 6:18am  Young women's breast cancers tend to be more aggressive and less responsive to therapy than the cancers that arise in older women, and scientists at the Duke Comprehensive Cancer Center and the Duke Institute for Genome Sciences and Policy may have discovered part of the reason why: young women's breast cancers share unique genomic traits that the cancers in older women do not exhibit........3 Oct 2008 at 6:18am  The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer. Eventhough patients with early stage, small, breast tumours have an excellent short term prognosis, more than 15 to 20 per cent of them will eventually develop distant metastases, and die from the disease. Vascular invasion - through lymphatic and blood vessels - is the major route for cancer spreading to regional lymph nodes and to the rest of the body........3 Oct 2008 at 6:18am  Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, as per data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancers........3 Oct 2008 at 6:18am  A unique genetic signature can alert physicians to high-risk breast tumors that are masquerading as low-risk tumors, as per research at Washington University School of Medicine in St. Louis and collaborating institutions. Eventhough these tumors are apparently estrogen-receptor positive meaning they should depend on estrogen to grow they don't respond well to anti-estrogen treatment........3 Oct 2008 at 6:18am  Using newly available data on worldwide cancer incidence, scientists at the Moores Cancer Center at University of California, San Diego (UCSD) and the Department of Family and Preventive Medicine have shown a clear association between deficiency in exposure to sunlight, specifically ultraviolet B (UVB), and breast cancer........25 Sep 2007 at 10:41pm  The Human Papillomavirus (HPV) is considered the cause of one of the most important sexually transmitted diseases nowadays, and affects both men and women. HPV is so common in our society that only people who have never had sexual relations can be sure that they have not been exposed to this disease. However, as with other microbes, people infected do not necessarily develop the disease, because, in most cases, it only means the colonization. Only some of the people colonized will fall ill with different processes........25 Sep 2007 at 10:41pm  University of Florida scientists have identified a set of proteins that appear to signal the presence of bladder cancer, a discovery they hope will lead to a simple, fast and noninvasive test that can detect the disease early. Working with colleagues at the University of Michigan, the researchers used advances in technology to isolate nearly 200 proteins from the urine of patients with and without bladder cancer. Several appear promising as potential biomarkers, including one that studies conducted elsewhere have already associated with liver and ovary cancer. The findings, available online, are scheduled would be reported in the July 6 print edition of the American Chemical Societys Journal of Proteome Research........25 Sep 2007 at 10:41pm  Arsenic exposure appears to continue causing lung and bladder cancer deaths years after exposure ends, as per a research studypublished online June 12 in the Journal of the National Cancer Institute Arsenic is a known cause of lung and bladder cancer, but scientists dont yet know how long cancer risk remains elevated after arsenic exposure. The drinking water in a region of northern Chile became contaminated with very high amounts of arsenic beginning in 1958. In the 1970s, construction of water therapy plants in the region led to a decline in arsenic concentration. This sudden rise and fall of arsenic levels gave scientists the opportunity to investigate the period between first and last exposure to high levels of arsenic and subsequent mortality due arsenic-related cancers, such as bladder and lung cancer........25 Sep 2007 at 10:41pm  There are currently about fifty million smokers in the U.S. and there are another fifty million ex-smokers. Cigarette smoking has been linked to several human malignancies. Some of these links like the relationship between smoking and lung cancer are well established. In some other cases the relationship between smoking and cancer is not very well established. However several studies have clearly shown the malignant potential of chemical substances in cigarette smoke. This article is an attempt to summarize some of the known links between cigarette smoking and caner........25 Sep 2007 at 10:41pm As you are aware we are the leading publishers of health news on the web. We publish news items in various forms including numerous blogs and news items. We invite you to participate in our new collection. We are looking for quality news items that would be interesting to our readers. Now you may suggest the news item from your site to be included at Medicineworld.org. Inclusion of news item at our site get instantaneous attention since the item is illustrated from various blog posts. Addition of pictures to the item adds additional attraction to your news item. Inclusion in the Medicineworld.org site brings quality links and visitors to your site........ 25 Sep 2007 at 10:41pm Medicineworld wishes all our readers merry Christmas. Oh, jingle bells, jingle bells Jingle all the way...... 25 Sep 2007 at 10:41pm Emory Winship Cancer Institute is the only cancer research and treatment facility in Georgia to offer an innovative Phase II clinical trial for transitional cell carcinoma (TCC), a common form of bladder cancer. The clinical trial is testing the efficacy of the investigational drug Vinflunine. Vasily Assikis, MD, assistant professor of hematology and oncology and director of Winship's Prostate Cancer Translational Research Program is principal investigator....... 25 Sep 2007 at 10:41pm A new population-based study has found that patients 75 years of age or older with invasive bladder cancer are less likely to receive the recommended surgical treatment for the disease.The findings "suggest in a sense some undertreatment of our older patients," Dr. Brenda K. Edwards of the National Cancer Institute, Bethesda, Maryland, told Reuters Health. However, she noted, the study was unable to gauge the influence of factors such as patient choice, which also could have made surgery less common among older patients....... 25 Sep 2007 at 10:41pm Previous research from Ohio State and Harvard Universities showed that men who ate broccoli had half the risk of bladder cancer compared to those who did not. Now the researchers have isolated interesting compounds from broccoli sprouts. Known as glucosinolates, they are turned into isothiocyanates during chopping, chewing and digestion. Experiments with bladder cancer cells, including the most aggressive type, shows that the isothiocyanates can block their growth. The scientist believe there may be up to a dozen other compounds in broccoli that have a similar effect....... |
2 Oct 2008 at 9:26am Hypnosis can help reduce hot flashes among breast cancer survivors, new research published in the Journal of Clinical Oncology shows. 1 Oct 2008 at 5:00pm Detection rates rival those of two radiologist readings, study says 1 Oct 2008 at 4:26pm In evaluating mammograms for breast cancer, a single reader with computer assistance can perform just as well as two readers, researchers have found. 30 Sep 2008 at 12:06pm 30 Sep 2008 at 10:54am An analysis of more than 300,000 patients has found that social class may influence what type of cancer you're at risk for. 30 Sep 2008 at 10:27am Genistein, a popular soy-based dietary supplement, can wipe out the effectiveness of a mainstay of breast cancer treatment known as aromatase inhibitor therapy, researchers warn based on animal experiments. 30 Sep 2008 at 9:26am Women who were bigger and longer babies may be more likely to develop breast cancer, researchers reported on Tuesday. 30 Sep 2008 at 9:00am Heavier, longer infants more likely to develop disease as adults, study finds 29 Sep 2008 at 11:27am Breast cancer survivors report feeling more fatigue and negative emotions in a typical day than their cancer-free peers, but round-the-clock monitoring demonstrates that their vital signs and level activity are no different, according to an international study. 26 Sep 2008 at 12:27pm Substances called heterocyclic amines (HAs) found in cooked meat and fish don't appear to boost a woman's risk of developing breast cancer after menopause, Swedish researchers report. 26 Sep 2008 at 8:24am Breast cancer survivors who still endure hot flashes may be helped by undergoing hypnosis, a new study has found. 25 Sep 2008 at 11:26am While raloxifene and tamoxifen are similarly effective in reducing breast cancer risk, raloxifene also appears to lower the risk of developing endometrial cancer, researchers report in the September 1st issue of the Journal of Clinical Oncology. 25 Sep 2008 at 10:26am Cases of breast cancer are expected to climb dramatically in China in the years ahead, researchers say, unless women avoid weight gain and limit their alcohol intake -- two leading risk factors for the disease. 25 Sep 2008 at 8:00am Patients using the technique saw episodes diminish by 68%, study finds 24 Sep 2008 at 4:26pm Gene mutations that increase the risk of breast cancer, known as BRCA1 and BRCA2, may occur more commonly in Asian women than previously thought, new research suggests. Finding BRCA mutations can have important implications for breast cancer prevention and treatment. |
by Lorenzo Melchor and Matthew J Smalley 6 Oct 2008 at 12:00am In recent years, the mammary gland epithelium has been shown to be a mixture of differentiated cell populations in a hierarchical relationship with their stem and progenitor cells. However, the mechanisms that regulate their cellular differentiation processes are still unclear. The identification of genes that govern stem and progenitor cell expansion, or that determine daughter cell fate, will be of crucial interest for understanding breast cancer diversity and, ultimately, improving treatment. Two recent analyses have identified some of the key genes that regulate these processes, lighting up the highway to normal mammary gland development. by Juergen Veeck, Nuran Bektas, Arndt Hartmann, Glen Kristiansen, Uwe Heindrichs, Ruth Knuchel and Edgar Dahl 30 Sep 2008 at 12:00am IntroductionExpression of the putative Wnt signaling inhibitor Dickkopf-3 (DKK3) is frequently lost in human cancer diseases due to aberrant 5'-cytosine methylation within the DKK3 gene promoter. Since other Wnt signaling inhibitors have been reported as targets of epigenetic inactivation in human breast cancer, we wondered whether DKK3 expression is epigenetically silenced during breast carcinogenesis as well and thus might contribute to oncogenic Wnt signaling commonly found in this disease. Methods: DKK3 mRNA expression and DKK3 promoter methylation were determined by RT-PCR, realtime PCR and methylation-specific PCR in breast cell lines (n = 9), normal breast tissues (n = 19), and primary breast carcinomas (n = 150), respectively. In vitro DNA demethylation was performed by incubating breast cell lines with 5-aza-2'-deoxycytidine and trichostatin A. DKK3 protein expression was analyzed by immunohistochemistry in breast carcinomas (n = 16) and normal breast tissues (n = 8). Methylation data were statistically correlated with clinical patient characteristics. All statistical evaluations were accomplished with SPSS 14.0 software. Results: DKK3 mRNA was downregulated in five of seven breast cancer cell lines and in 68% of primary breast carcinomas (n = 40) compared with benign cell lines and normal breast tissues, respectively. A DNA demethylating treatment of breast cell lines resulted in strong induction of DKK3 mRNA expression. In tumorous breast tissues, DKK3 mRNA downregulation was significantly associated with DKK3 promoter methylation (P < 0.001). Of the breast carcinomas, 61% (92/150) revealed a methylated DKK3 promoter whereas 39% (58/150) retained an unmethylated promoter. Loss of DKK3 expression in association with DKK3 promoter methylation (P = 0.001) was also confirmed at the protein level (P < 0.001). In bivariate analysis, DKK3 promoter methylation was not associated with investigated clinicopathological parameters except patient age (P = 0.007). Conclusions: DKK3 mRNA expression and consequently DKK3 protein expression become frequently downregulated during human breast cancer development due to aberrant methylation of the DKK3 promoter. Since DKK3 is thought to negatively regulate oncogenic Wnt signaling, DKK3 may be assigned a potential tumor suppressor gene in normal breast tissue. by Katja Lundgren, Karolina Holm, Bo Nordenskjold, Ake Borg and Goran Landberg 29 Sep 2008 at 12:00am IntroductionThe amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer patients. Overexpression of cyclin D1 protein however, confers tamoxifen resistance but not a tamoxifen induced adverse effect. Potentially, co-amplification of an additional 11q13 gene, with a resulting protein overexpression, is required to cause an agonistic effect. Moreover, during 11q13 amplification a deletion of the distal 11q region has been described. In order to assess the potential impact of the deletion we have examined a selected marker for this event.MethodArray comparative genomic hybridization analysis was employed to identify and confirm changes in the gene expression of a number of different genes mapping to the 11q chromosomal region, associated with CCND1 amplification. The subsequent protein expression of these candidate genes was then examined in a clinical material of 500 primary breast cancers from premenopausal patients randomized to either tamoxifen or no adjuvant treatment. The protein expression was also compared to the gene expression data in a subset of 56 breast cancer samples. Results: Cortactin and FADD overexpression was linked to CCND1 amplification, determined by fluorescent in situ hybridization, but was not associated with a diminished effect of tamoxifen. However, deletion of distal chromosome 11q, defined as downregulation of the marker Chk1, was associated with an impaired tamoxifen response, and interestingly, also with low proliferative breast cancer of low grade. For Pak1 and cyclin D1 the protein expression corresponded to the gene expression data. Conclusion: The results indicate that many 11q13 associated gene products are overexpressed in conjunction with cyclin D1 but not linked to an agonistic effect of tamoxifen. Finally, the deletion of distal 11q, linked to 11q13 amplification, might be an important event affecting breast cancer outcome and tamoxifen response. by Galatea Kallergi, Sofia Agelaki, Antonia Kalykaki, Christos Stournaras, Dimitris Mavroudis and Vassilis Georgoulias 29 Sep 2008 at 12:00am IntroductionThe PI-3 kinase/Akt pathway, operating downstream of EGFR and HER2, is implicated in cell migration and survival. EGFR and HER2 are expressed in circulating tumor cells, however, the activation status of downstream signaling molecules has not yet been reported. Methods: To investigate EGFR/HER2/PI-3 kinase/Akt expression in circulating tumor cells, we used peripheral blood mononuclear cells from 32 cytokeratin-19 mRNA-positive patients with early (n=16) and metastatic (n=16) breast cancer. PBMC cytospins were double stained with cytokeratin antibody along with either of the following: EGFR, phospho-EGFR, HER2, phospho-PI-3 kinase or phospho-Akt antibodies, respectively. Results: EGFR and HER2 were expressed in circulating tumor cells of 38% and 50% patients with early and 44% and 63% patients with metastatic disease, respectively. Interestingly, phospho-PI-3 kinase and phospho-Akt expressions were similar at 88%(14 out of 16) and 81% (13 out of 16), respectively, in circulating tumor cells of patients with early and metastatic disease. Phospho-EGFR was observed in circulating tumor cells of two (33%) early and six (86%) metastatic EGFR-positive patients. Immunomagnetic separation of peripheral blood mononuclear cells, using EpCAM antibody and subsequent double staining experiments of circulating tumor cells showed that EGFR was co-expressed with HER2, phospho-Akt and phospho-PI-3 kinases, indicating activation of the corresponding survival signaling pathway. Conclusions: Our findings demonstrate that circulating tumor cells express receptors and activated signaling kinases of the EGFR/HER2/PI-3 kinase/Akt pathway which could be used as targets for their effective elimination. by Rulla M Tamimi, Stuart J Schnitt, Graham A Colditz and Laura C Collins 26 Sep 2008 at 12:00am No Abstract by Rohit Bhargava and David J Dabbs 26 Sep 2008 at 12:00am This is a letter regarding a recently published article in Breast Cancer Research by Tamimi et al (Breast Cancer Res 2008, 10(4):R67). Concerns regarding categorization of breast cancer molecular classes using surrogate immunohistochemical markers are discussed. by Signe Borgquist, Annika Jögi, Fredrik Pontén, Lisa Rydén, Donal J Brennan and Karin Jirström 22 Sep 2008 at 12:00am IntroductionWe have previously reported that tumour-specific expression of the rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR), in the mevalonate pathway is associated with more favourable tumour parameters in breast cancer. In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up. Methods: The expression of HMG-CoAR was assessed by immunohistochemistry on tissue microarrays with tumour specimens from 498 consecutive cases of breast cancer with a median follow-up of 128 months. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the rate of recurrence-free survival (RFS) and breast cancer specific survival (BCSS). Results: In line with our previous findings, tumour-specific HMG-CoAR expression was associated with low grade (p < 0.001), small size (p = 0.007), oestrogen receptor (ER) positive (p = 0.01), low Ki-67 (p = 0.02) tumours. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS, even when adjusted for established prognostic factors (relative risk [RR] = 0.60, 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In ER-negative tumours, however, there was a trend, that was not significantly significant, towards a shorter RFS in HMG-CoAR expressing tumours. Conclusions: HMG-CoAR expression is an independent predictor of a prolonged RFS in primary breast cancer. This may, however, not be true for ER-negative tumours. Further studies are needed to shed light on the value of HMG-CoAR expression as a surrogate marker of response to statin treatment, especially with respect to hormone receptor status. by Lena U Rosenberg, Fredrik Granath, Paul W Dickman, Kristjana Einarsdottir, Sara Wedren, Ingemar Persson and Per Hall 19 Sep 2008 at 12:00am IntroductionMenopausal hormone therapy has been reported to increase the risk of certain subtypes of breast cancer and to be associated with a favorable survival. This could either be due to an increased mammographic surveillance or a biological effect. We assessed these associations in a Swedish cohort of postmenopausal breast cancer patients holding information on mammographic examinations, menopausal hormone therapy use, other breast cancer risk factors, and cancer treatment. Methods: We analyzed 2,660 postmenopausal women aged 50-74 years, diagnosed with invasive breast cancer in 1993-1995 and followed until the end of year 2003 (median follow-up 9 years and 3 months). We assessed the influence of hormone therapy before diagnosis on tumor characteristics and breast cancer specific survival. We analyzed hormone therapy before diagnosis by regimen (estrogen-progestin therapy or estrogen alone therapy), recency (current or past), and duration of use (<5 years or [greater than or equal to]5 years). Results: Current, but not past use, compared to never use of hormone therapy before diagnosis seemed to be associated with tumors of low grade and improved breast cancer specific survival. The associations were stronger with longer duration, but did not vary significantly by regimen. The favorable survival among current users of hormone therapy was only partly explained by differences in available tumor characteristics and mammographic surveillance. Conclusions: We conclude that current menopausal hormone therapy, especially long-term, is associated with favorable tumor characteristics and survival. by Valerie Speirs 19 Sep 2008 at 12:00am Controversy surrounds the potential clinical importance of oestrogen receptor (ER)β in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERβ1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERβ1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERβ2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERβ2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERβ in breast cancer and shall be discussed. by Sibylle Loibl, Gunter von Minckwitz, Nadia Harbeck, Wolfgang Janni, Dirk Elling, Manfred Kaufmann, Holm Eggemann, Valentina Nekljudova, Harald Sommer, Marion Kiechle and Sherko Kummel 16 Sep 2008 at 12:00am IntroductionDespite the fact that patients above 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases. Furthermore, most physicians tend to therapy regimens without the use of dose dense-highly active taxane based treatments because a lack of data regarding toxicities of these compounds in elderly patients. Methods: Pooled side-effect data were analyzed from four prospective, randomized clinical trials in which patients of different age groups (< 60 years, between 60 and 64 years and above 64 years) with primary breast cancer received taxane-based chemotherapy. Results: Dose delays, dose reductions, hospitalization, therapy discontinuation were increasing with age. Hematologic toxicities and some non-hematologic toxicity were generally more common in elderly patients. Leucopenia increased from 55.3% in patients below 60 to 65.5% in patients older than 64 years (p<.001) and neutropenia from 46.9% to 57.4% (p<.001). But there was no difference in clinically more realevant febrile neutropenia between the different age groups. Thrombopenia shows a similar age dependent increase whereas there is no difference between the age groups concerning anemia. Hot flushes and elevated liver enzymes decreased with increasing age. Conclusions: This pooled analysis of a substantial cohort of elderly primary breast cancer patients demonstrates that taxane-containing (neo-) adjuvant chemotherapy is feasible in the elderly patients and that toxicity can be reduced by sequential therapy regimens. |
6 Oct 2008 at 10:00am Computer-aided detection software for mammograms is nearly as effective as a second radiologist reading the test results to determine the presence of breast tumors, according to a study published on Thursday in the New England Journal of Medicine, 6 Oct 2008 at 7:00am Despite recent examples of young and middle-aged celebrities being diagnosed with breast cancer, more than half of breast cancers happen in women over age 65. That's why experts at the University of Michigan Comprehensive Cancer Center recommend women continue to receive yearly breast screenings through their 70s. "Women don't seem to take the risk of breast cancer as they get older seriously. 6 Oct 2008 at 4:00am Postmenopausal women in the UK could be unknowingly missing out on optimal follow-up treatment for breast cancer, according to research presented today at the annual National Cancer Research Institute (NCRI) Cancer Conference. 6 Oct 2008 at 4:00am Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance. However, it's vital that this is backed up by formal audits to ensure that all patients receive the best treatments for them. 5 Oct 2008 at 7:00am Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind, reports a study in the October issue of Genetics in Medicine, official journal of the American College of Medical Genetics (ACMG). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. 5 Oct 2008 at 2:00am The American College of Obstetricians and Gynecologists (ACOG) will again serve as a national co-sponsor for National Breast Cancer Awareness Month (NBCAM). ACOG is proud to work with NBCAM and other organizations at the forefront of women's health and breast cancer research to offer educational resources and services to help women prevent, detect, manage, and treat the disease. Today, there are 2. 4 Oct 2008 at 4:00am The University of Texas M. D. Anderson Cancer Center has received nearly $19 million in grants from Susan G. Komen for the Cure® as part of that organization's new initiative to fast-track promising research to benefit breast cancer patients. Ranging from $120,000 to $7.5 million, the grants will be allocated across 11 different translational breast cancer research studies with the intent to bring treatments from the laboratory to patient care as quickly as possible. 3 Oct 2008 at 1:00pm Coinciding with the observance of Nuclear Medicine Week (October 5 to 11) and National Breast Cancer Awareness Month (October), SNM has released a new fact sheet highlighting recent developments in molecular imaging technologies that are dramatically improving the ways in which breast cancer is diagnosed and treated. Molecular imaging is a highly effective, safe and painless imaging tool for diagnosing and treating breast cancer. 3 Oct 2008 at 8:00am Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say. About 70 percent of breast cancer cells have receptors for the hormone estrogen, which acts as a nutrient and stimulates their growth. Patients typically get an antiestrogen such as tamoxifen for five years to try to starve them to death, says Dr. Patricia V. Schoenlein, cancer researcher in the Medical College of Georgia Schools of Medicine and Graduate Studies. 3 Oct 2008 at 7:00am Join the live lumpectomy surgery to remove early stage breast cancer and prepare the surgical site for IntraBeam(R), intraoperative radiation therapy that occurs right in the operating room. From Sentara CarePlex Hospital in Hampton, Virginia with surgical oncologist Dr. Richard C. Hoefer and radiation oncologists Dr. Michael Miller and Dr. Song Kang IntraBeam(R) is a registered trademark of Carl Zeiss Meditec, Inc. 3 Oct 2008 at 5:00am A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. Results of a UC Davis study, however, show that a number of women whose cancer recurs in the same breast are treated with a second lumpectomy rather than a mastectomy, defying current treatment recommendations and cutting the number of years those women survive in half. 3 Oct 2008 at 5:00am A novel endoscopic-assisted technique for skin-sparing mastectomy with immediate breast reconstruction can successfully treat early breast cancer patients while offering favorable aesthetic results. Researchers of a study in 3 Oct 2008 at 3:00am Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. Dr. George Peoples, Deputy Director, United States Military Cancer Center, co-authored a publication that appears on the cover of the October 1, 2008, issue of Cancer (Vol.113 Issue 7:1666-75) and details the Phase I/II clinical study results. 3 Oct 2008 at 2:00am Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. 3 Oct 2008 at 2:00am UK researchers found that the rate of detection of breast cancer by two experts reading a mammogram was the same as one expert using computer aided detection, but there was a slightly but significantly higher recall rate in the computer assisted method. |
|
All information in this site is deemed reliable but not guaranteed. Garypedia.com web site owner shall
not be responsible for any typographical errors, misinformation, and misprints and shall be held totally harmless individually.Garypedia.com is an independent provider of links to news articles. Garypedia.com contains links to sites on the internet which are owned and operated by the "External Sites". Garypedia.com is not responsible for the availability of any External Sites. Contact the site administrator or Webmaster for those External Sites if you have any concerns regarding such links or the links located on such External Sites. Garypedia.com is entirely committed to protecting the privacy of its mediapartners and their users. We use a browser feature known as a cookie. One way our cookies are useful is that they help to improve and personalize your experience by increasing a page's responsiveness and decreasing time between downloading as you browse or surf through the site. Additionally, a pixel tag is delivered with the newsfeeds themselves to organize information about online activity as a means to create anonymous profiles that reflect content preferences. No personally identifiable information is stored or collected. Any suggestions, please email us.
Copyright © 2007 Garypedia.com. All rights reserved. |
breast cancer